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A blaCTX-M-15 gene is one of the most prevalent resistant marker found in member
of enterobacteriaceae. It encodes cefotaxime hydrolysing β-lactamase-15 (CTX-M-15)
causing resistance against beta lactam antibiotics. Since single antibiotic therapy fails to
control infection caused by multidrug resistance strain, therefore combination therapy
was came into practice as an effective treatment. We have first time explained the
mechanism where two antibiotics of different classes work against resistant strains.
Binding parameters obtained by spectroscopic approach showed significant interaction
and complex formation between drugs and CTX-M-15 enzyme with decreased ksv and
kq values. CD analysis showed altered conformation and significant changes in alpha
helical content of CTX-M-15 enzyme on interaction with streptomycin in combination with
cephalosporin. Steady state kinetics revealed decrease in hydrolytic efficiency of enzyme
to about 27% by cooperative binding behavior upon sequential treatment of enzyme
with streptomycin and cefotaxime. Therefore, the study concludes that combination
therapy against CTX-M-15 producing strain with Cefotaxime/Streptomycin in 1:10 molar
ratio, decreases CTX-M-15 efficiency significantly because of the fact that streptomycin
induced structural changes in CTX-M-15 hence cefotaxime was not properly bound on
its active site for hydrolysis rather available for the target to inhibit bacterial cells.
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INTRODUCTION
β-lactamases are the group of enzymes that cleave amide bond in beta lactam rings of beta lactam
antibiotics rendering them harmless to bacteria. Production of these enzymes is the predominant
cause of gram negative bacterial resistance against β-lactam antibiotics which has become a major
health concern (Bonnet, 2004; Bush, 2010a).
In Enterobacteriaceae, ESBLs (Extended spectrum beta lactamases) encoding CTX-M type
markers on plasmid, are reported worldwide (Coque et al., 2008; Hawkey and Jones,
2009). It hydrolyzes the oxyimino-cephalosporin and cefotaxime with about 1000-fold higher
catalytic efficiency than other class A β-lactamases (Bauernfeind et al., 1992; Bonnet, 2004).
CTX-M type ESBLs display greater hydrolytic activity against Cefotaxime than Ceftazidime
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(Bonnet, 2004). CTXM-15 is the widely spread ESBL in India and
is reported in widemembers of Enterobacteriaceae family (Karim
et al., 2001). It has been reported that bacteria expressing ESBLs
are resistant toward various β-lactam antibiotic groups such as
Penicillins, different generations of Cephalosporins, Aztreonam
and also to various antibiotic /inhibitor combinations (Faheem
et al., 2013).The widespread dissemination of CTX-M-15 by E.
coli and other enteric bacilli has a significant impact on hospital
and community-acquired infections (Bush, 2010b; Chen et al.,
2014).
It has been observed that treatment with single antibiotic
fails to cure increasing microbial infections due to emergence
of antibiotic resistance. For e.g., studies performed on other
β-lactamases such as OXA-51 in Acinetobacter baumannii
shows how carbapenem antibiotic is hydrolyzed by β-
lactamases leading to the survival of the pathogen (Tiwari and
Moganty, 2014) Therefore, it is an augmented need to employ
combination therapy and to understand pharmacological and
pharmacodynamic (Lin et al., 1987) behavior of multiple drugs
for rational basis of antibiotics selection for effective treatment
in order to avoid antagonism between certain antibiotics as
demonstrated earlier (Gunnison et al., 1950).
A marked increase in bactericidal effect in vitro by synergistic
treatment with penicillin and streptomycin has been reported
earlier (Jawetz et al., 1951), compared to single drug treatment
(Gunnison et al., 1950). An observation which is consistent
with a hypothesis that streptomycin faces natural barrier while
entering enterococci which can be prevailed by agents inhibiting
cell wall synthesis such as penicillin and hence can produce
synergistic effect (Moellering and Weinberg, 1971). We have
already reported earlier that the synergistic effect of cefoxitin with
streptomycin and cefotaxime proved an effective combination
against multidrug resistant bacterial strains (Hasan et al., 2013).
The mechanism behind effective nature of drugs of two
different classes in combination has not yet been explained.
Therefore, this is the first time we have initiated this work
to understand the molecular mechanism behind synergy of
cephalosporin and aminoglycoside against multidrug resistance
strains. The hypothesis proposed was that streptomycin might
induce structural changes in CTX-M-15 enzyme on binding,
hence may not allow cefotaxime to properly bind and hydrolyze,
as a result cefotaxime is available for target site inhibition in
bacterial cells.
MATERIALS AND METHODS
Protein/Enzyme Source
CTX-M-15 from Enterobacter cloacae clinical strain, EC-15
(Genebank accession no.: JN860195.1) (Chen et al., 2014) E. coli
BL21 (DE3), pQE-2 (high copy cloning vector).
Antibiotics and Other Chemicals
Cefotaxime and Cefoxitin were purchased from Sigma chemical
co. (St. Louis, MO), Streptomycin from Himedia (India), IPTG
Abbreviations: ESBLs, Extended spectrum beta lactamases; IPTG, Isopropyl-β-D-
1-thiogalactopyranoside; PBS, phosphate buffer saline; CD, Circular Dichroism.
(isopropyl-β-D-1-thiogalactopyranoside) was purchased from
Roche (Basel, Switzerland). Nitrocefin was purchased from
Calbiochem (USA). Imidazole was purchased from Sigma-
Aldrich. Other reagents and chemicals were of analytical
grade and double distilled water was used throughout the
study.
blaCTX-M-15 Cloning and Expression of
CTX-M-15
The plasmid DNA carrying blaCTXM-15 gene cloned from
clinical E. cloacae EC-15 strain (Genebank accession
no.: JN860195.1), was extracted using Qiagen plasmid
extraction kit, according to manufacturer’s instructions.
The blaCTX-M-15 was amplified by PCR using primers
CTX-M-15-F (5′ ATATCATATGGTTAAAAAATCACTG
3′) containing Nde I restriction site and CTX-M-15-R (5′
ATATAAGCTTTTACAAACCGTCGGTGAC 3′) containing
Hind III restriction site. The PCR conditions used were 95◦C
for 30 s, 54◦C for 25 s, 72◦C for 40 s and the reaction process
was carried out for 35 cycles (Faheem et al., 2013). The PCR
product does not contain the promoter region of the gene.
The PCR product and pQE-2 (high copy cloning vector), were
double digested with NdeI and Hind III endonucleases, ligated
and transformed into competent E. coli BL21 (DE3) cells by
heat shock method (4◦C for 30min, 42◦C for 90 s and 4◦C
for 10min). Transformants harboring blaCTX-M-15 gene were
selected on LB agar plates containing ampicillin (100µg/ml).
The clones were confirmed by double restriction digestion
of obtained transformed cells by NdeI and HindIII enzymes
(Figure S1) and sequencing by standard procedures.
To express and purify CTXM-15 β-lactamase, the competent
cells of E. coli BL21 (DE3) harboring pQE-2 vector carrying
blaCTX-M-15 gene, a 10ml overnight culture of these transformed
cells in Luria-Bertani broth containing 100 µg/ml ampicillin was
used to inoculate 1 l of Luria-Bertani broth containing 100µg/ml
ampicillin. Bacterial culture was grown at 37◦C with shaking
at 120 rpm, until an optical density of 0.6–0.8 was reached
at 600 nm (Faheem et al., 2013). The culture was cooled and
induced with 0.2mM IPTG and placed at 16◦C at 150 rpm for
12–16 h. The bacterial cells were collected by centrifugation and
re-suspended in 20ml lysis buffer containing 50 mM Sodium
phosphate (pH 8.0), 300mM NaCl and 10mM Imidazole along
with 0.1% β-mercaptoethanol per liter culture. The bacterial cells
were ruptured by sonication at 35% amplitude for 10 min, and
the cell debris obtained was removed by centrifugation at 12,000
rpm for 30min. The clear supernatant was loaded onto a Ni-NTA
column, which was pre-equilibrated by lysis buffer, and washed
with lysis buffer supplemented with 50mM imidazole. Protein
was eluted with PBS (Phosphate buffer saline, 50mM sodium
phosphate (pH 8.0) containing 300mM NaCl) buffer containing
250mM imidazole. Pure protein was obtained after dialysis in
PBS. Purity of the purified protein was estimated to be more than
97% as determined by a single band of 31 kDa on SDS-PAGE
(Figure S2). The final protein concentrations were determined by
using the molar extinction coefficient of 25, 440 M−1 cm−1 at
280 nm.
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FIGURE 1 | Stern-Volmer plots for drug induced fluorescence quenching of CTX-M-15. At 298K under different drug incubations, the Stern-Volmer plots for
CTX-M-15- drug interactions is shown. The concentration of CTX-M-15 was 2µM and the concentration of the bounded drug was 20 µM in 50mM sodium
phosphate buffer at pH 7.4.
TABLE 1 | Stern−Volmer quenching constants and binding parameters for
CTX-M-15 and Cefotaxime/Streptomycin/Cefoxitin interactions.
Ksv(M−1) Kq(M−1s−1) Ka(M−1) n R2
CTX-M-15+CTX 14.6 × 104 3.38 × 1013 0.297 × 104 0.633 0.995
CTX-M-
15+CTX+FOX
3.2 × 104 0.74 × 1013 0.037 × 104 0.558 0.993
CTX-M-
15+CTX+FOX+STR
2.8 × 104 0.64 × 1013 0.361 × 104 0.794 0.991
CTX-M-
15+CTX+STR
1.2 × 104 0.278 × 1013 0.126 × 104 0.773 0.994
CTX-M-
15+CTX+STR+FOX
3.2 × 104 0.742 × 1013 1.253 × 104 0.904 0.991
CTX-M-15+STR 4.4 × 104 1.02 × 1013 0.019 × 104 0.47 0.997
CTX-M-
15+STR+CTX
8.2 × 104 1.902 × 1013 2.904 × 104 0.916 0.993
CTX-M-
15+STR+FOX
2.5 × 104 0.58 × 1013 0.162 × 104 0.729 0.992
CTX-M-
15+STR+FOX+CTX
4.2 × 104 0.974 × 1013 2.023 × 104 0.944 0.994
CTX, cefotaxime; STR, streptomycin; FOX, cefoxitin.
Fluorescence Spectra Measurements
All the fluorescence study was done on a Shimadzu RF-
5301PC spectrofluorometer (Shimadzu Corporation, Kyoto,
Japan) which is equipped with a thermostatically controlled
cell holder and attached to a water bath to maintain desired
constant temperature. Fluorescence quenching was monitored
by measuring intrinsic fluorescence quenching of protein to
elucidate the mechanism of its interaction with drug molecule
(Eftink and Ghiron, 1976; Lakowicz, 1988) between 300 and
450 nm after selectively exciting the sample at 295 nm, both
the excitation and emission slits were set at 5 nm and the
spectra were recorded at fast scanning mode. To a 3 mL sample
containing 2µM CTX-M-15 protein alone or incubated with
20µM of cefotaxime, cefoxitin and streptomycin each in various
combinations and by successive direct addition of 2µM of each
drug in such a manner that the total volume added was not
more than 40µL at 298 K. All the fluorescence intensities were
corrected for the inner filter effect. The decrease in fluorescence
intensity of protein at emission maxima was analyzed by using
the Stern-Volmer equation (Lakowicz, 1988):
F◦/F = 1+ Ksv[Q] = 1+ Kqτ◦[Q] (1)
where F◦ and F are the fluorescence intensities in the absence and
presence of drug (quencher), KSV is the Stern-Volmer constant,
[Q] is the molar concentration of quencher, and kq and τ◦ are
the bimolecular quenching rate constant and the lifetime of the
protein fluorescence in the absence of quencher, respectively. The
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FIGURE 2 | Modified Stern−Volmer plots for the quenching of CTX-M-15. At 298K under different drug incubations, the Modified Stern-Volmer plots for
CTX-M-15- drug interactions is shown. The concentration of CTX-M-15 was 2µM and the concentration of the bounded drug was 20µM in 50mM sodium
phosphate buffer at pH 7.4.
bimolecular rate constant Kq was calculated from the relation:
Kq = Ksv/τ◦ (2)
where τ◦ is the mean fluorescence life time of Trp which is ∼
4.31 × 10−9 s. The binding constant (Ka) and the number of
binding sites (n) were calculated using the following modified
Stern-Volmer equation (Kang et al., 2004):
log
F◦ − F
F
= logKa+ nlog[Q] (3)
CD Spectra Measurements
CD spectra were collected on a Jasco J-810 spectropolarimeter
(Jasco International Co. Ltd., Tokyo, Japan) equipped with a
Peltier-type temperature controller (PTC-423S/15) and attached
to a water bath. Far-UV CD spectra of CTX-M-15 in the
absence and presence of drugs (1:10) (Micro molar ratio) were
taken at protein concentrations of 5µM in 0.1 cm path length
cells, respectively and all the spectra were corrected for the
appropriate blanks. The instrument was calibrated with (+)-10-
camphorsulfonic acid. All the spectra were measured at 298K
using a scan speed of 100 nm/min and the response time of 1 s.
The observed ellipticity obtained is converted to mean residual
ellipticity [MRE] in deg.cm2.dmol−1 by using the following
equation (Rehman et al., 2015):
MRE =
[θ]obs
10ncl
(4)
Where [θ]obs is the observed ellipticity in mdeg, n is the total
number of amino acid residues (291) in CTX-M-15 protein, c is
the molar concentration of the protein, and l is the path length in
cm. The α-Helical content of drug treated and untreated CTX-M-
15 was calculated from the MRE values at 208 and 222 nm using
the following equation (Chen et al., 1972):
%α− helix =
[
[MRE]208nm− 4000
33000− 4000
]
∗ 100 (5)
% ∝ − helix =
[
[MRE] 222nm− 2340
30300
]
∗ 100 (6)
Steady-State Kinetics Experiments
Enzyme kinetics measurements were recorded on a Shimadzu
UV-1800 double beam spectrophotometer (Shimadzu
International Co. Ltd., Kyoto, Japan) at 298 K.
The hydrolysis activity of CTX-M-15 toward a chromogenic
cephalosporin substrate Nitrocefin was studied (O’Callaghan
et al., 1972). Steady-state enzyme kinetics was performed
by directly monitoring the initial velocities of appearance
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FIGURE 3 | Far-UV CD spectra of CTX-M-15. CD spectra of CTX-M-15 alone or in complex with cefotaxime alone or along with streptomycin/cefoxitin or both at
1:10, 1:10:10, and 1:10:10:10 molar ratio was taken. The concentration of CTX-M-15 and cefotaxime/streptomycin/cefoxitin was 5 and 50µM in 50mM Sodium
phosphate buffer pH 7.4 at 298 K.
or disappearance of chromophore, Nitrocefin. The effect of
Cefotaxime, Streptomycin, and Cefoxitin binding on the catalytic
activity of CTX-M-15 toward Nitrocefin was determined by
steady state kinetics at pH 7.4 in 50mMphosphate buffer and 298
K. The concentration of CTX-M-15 enzyme was kept constant at
8.75 nM, (for dilution of the enzyme and to prevent denaturation,
BSA was added to a final concentration of 20µg/ml (Galleni
et al., 1994), we found that BSA at the concentration used in
the experiment did not show any effect on the hydrolytic ability
of CTX-M-15), while the concentration of nitrocefin was varied
from 0 to 650µM. CTX-M-15 activity in presence of 87.5 nM of
each drug, cefotaxime, streptomycin and cefoxitin was obtained
by incubating them for 1.5 h with enzyme at room temperature.
The rate of Nitrocefin hydrolysis was determined by measuring
the appearance of nitrocefin (red colored product) at 486 nm
for 65 s. All the measurements were performed on Shimadzu
UV-1800 double beam spectrophotometer. The concentration
of nitrocefin was determined by measuring absorbance using a
molar extinction coefficient value of 15,000 M−1cm−1 at 486
nm. The kinetic parameters (kcat and Km) were determined
according to the Michaelis-Menten method by fitting the data to
the following equations.
v =
Vmax[S]
Km+ [S]
(7)
Kcat =
Vmax
[E]
(8)
RESULTS
The blaCTX-M-15 gene was cloned and transformants harboring
blaCTX-M-15 gene were confirmed by double restriction digestion
using NdeI and HindIII enzymes for its presence. Agarose gel
of double digestion showed two bands of 4.8 kb corresponding
to pQE-2 vector and 800 bp corresponding to blaCTX-M-15
gene (Figure S1).Purity of the protein obtained after dialysis
in PBS was estimated to be more than 97% as determined
by single band of 31 kDa on SDS-PAGE (Figure S2). The
final protein concentrations were determined to be 1.5mg/ml
using the molar extinction coefficient of 25, 440M−1 cm−1 at
280 nm.
Fluorescence spectra measurements showed the effect of
single and combination of drug binding on the fluorescence
property of CTX-M-15 (Figures S3, S4). A progressive decrease
in the fluorescence intensity was observed due to quenching of
CTX-M-15 fluorescence. The data were analyzed according to
the Stern-Volmer Equations (1) and (2) (Figure 1, Table 1). The
binding constant (Ka) lying in the range of 102–104 M−1 and
the number of binding sites (n) which was found to be one, were
determined usingmodified Stern-Volmer Equation (3) (Figure 2,
Table 1). KSV values for interactions with different drugs were of
the order of 104 M−1. The kq values were determined from the
ratios of KSV/τo after taking τo for CTX-M-15 = 4.31 × 10
−9s.
The kq values were of the order of 1012–1013 M−1s−1.
Far-UV CD spectrum characterizes the conformation of the
peptide backbone to determine secondary structure (α-helices
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FIGURE 4 | Far-UV CD spectra of CTX-M-15. CD spectra of CTX-M-15 alone or in complex with streptomycin alone or along with cefotaxime/cefoxitin or both at
1:10, 1:10:10, and 1:10:10:10 molar ratio was taken. The concentration of CTX-M-15 and streptomycin/cefotaxime/ cefoxitin was 5 and 50µM in 50 mM Sodium
phosphate buffer pH 7.4 at 298 K.
TABLE 2 | Spectral characteristics of CTX-M-15 under different drug binding conditions.
MRE208 (deg.cm
2.dmol−1) % α helix at 208 MRE222 (deg.cm
2.dmol−1) % α helix at 222
CTX-M-15 −14, 070±210 34.72% −14, 004.9± 145 38.49%
CTX-M-15+CTX −12, 500.1±161 29.31% −20, 842.9± 132 61.06%
CTX-M-15+CTX+STR −20, 524.3±170 56.98% −30, 313.2± 126 92.32%
CTX-M-15+CTX+FOX −7, 744.89±157 12.91% −21, 163.5± 201 62.12%
CTX-M-15+CTX+FOX+STR −10, 322.8±190 21.8% −22, 061.1± 138 64.93%
CTX-M-15+CTX+STR+FOX −12, 871±173 30.58% −26, 010.9± 223 78.12%
CTX-M-15+STR −10, 760.6±102 23.3% −20, 096.1± 139 58.60%
CTX-M-15+STR+CTX −21, 577.9±189 60.61% −27, 178.1± 159 81.97%
CTX-M-15STR+FOX −12, 972.1±144 30.93% −21, 621.4± 149 63.63%
CTX-M-15+STR+FOX+CTX −11, 166.3±204 24.71% −27, 848.7± 187 84.81%
CTX, cefotaxime; STR, streptomycin; FOX, cefoxitin.
MRE values are reported as the average of ± standard error from three independent experiment.
and β-sheets) of the protein. Hence the possible effects of
(single/combination) drug on the secondary structure of CTX-
M-15 was monitored by CD spectroscopy in the far-UV region
(250–200) and the results are shown in Figures 3, 4. CTX-M-15,
in the absence of drug showed two negative bands at 208 and 222
nm which is a characteristic of the α-helix protein with minima
at 208 and 222 nm. The far-UV CD spectra of CTX-M-15 closely
resembled to that of the CTX-M-1 (Perez-Llarena et al., 2011).
MRE (mean residual ellipticity) and % alpha helical content
of the protein calculated are shown in Table 2. The MRE208
nm and MRE222 nm of CTX-M-15 under native condition,
without any drug treatment was found to be −14,070 and
−14,004.9 deg cm2 dmol−1 respectively (Table 2), with alpha
helical content of 34.72 and 38.49% as calculated from Equations
(5) and (6). In the presence of drug combinations, CTX-M-15
showed remarkable distortion in the alpha helical content with
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FIGURE 5 | Michaelis-Menten plot. Steady-state kinetics of Nitrocefin hydrolysis by CTX-M-15 in the absence and presence of different combinations of (A)
Cefotaxime/Streptomycin/Cefoxitin and (B) Streptomycin/ Cefotaxime/Cefoxitin at 298K was carried out. The concentration of CTX-M-15 was 8.75 nM while the
concentration of drugs were 87.5 nM in 50mM sodium phosphate buffer, pH 7.4.
maximum disruption in streptomycin and cefotaxime bounded
CTX-M-15.
The steady-state kinetics of the purified CTX-M-15 was
carried out on nitrocefin, a chromogenic cephalosporin substrate
which revealed a hydrolytic profile that is a characteristic of
molecular class A beta lactamase. The representative Michaelis-
Menten plots are shown in Figure 5 and the deduced kinetic
parameters (kcat, Km, and kcat/Km) are summarized in
Table 3. The catalytic activity of CTX-M-15 was investigated on
nitrocefin to ascertain the involvement of CTX-M-15 in drug
binding. The Michaelis-Menten plots of nitrocefin hydrolysis
at 1:10, 1:10:10, 1:10:10:10 molar ratios of different CTX-M-
15: cefotaxime/streptomycin/cefoxitin, drug combinations were
analyzed to check if kcat and Km values in any case being
reduced. The kinetic data were also plotted as Lineweaver-Burk
plots to infer the kinetic parameters by which drug inhibited
the hydrolysis activity of CTX-M-15 (Figure 6). We found
increased Km values for all CTX-M-15 drug incubations except
for cefotaxime alone with CTX-M-15, implying the decrease in
the affinity of enzyme toward substrate nitrocefin in the presence
of streptomycin and in all studied combination of streptomycin
and cephalosporin drugs treatment. Similarly we found decreased
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TABLE 3 | Steady-State Kinetic Parameters for Hydrolysis activity of
CTX-M-15 in presence of various drugs.
Km (µM) Kcat (s−1) Kcat/Km
(µM−1s−1)
CTX-M-15 only 88.13 ± 0.5 7618.97 ± 1.4 86.451
CTX-M-15+ CTX 65.932 ± 0.9 7618.97 ± 0.85 115.557
CTX-M-15+ STR 93.789 ± 1.0 6015.02 ± 0.3 64.133
CTX-M-15+STR+CTX
(Allosteric curve)
∼ 100 ± 2.0 ∼ 6285 ± 3.1 ∼ 62.85
CTX-M-15+STR+FOX 187.212 ± 1.6 8163.2 ± 2.5 43.604
CTX-M-15+CTX+STR 180.363 ± 1.8 10389.6 ± 0.4 57.603
CTX-M-15+CTX+FOX 304.45 ± 0.9 10389.6 ± 2.2 34.12
CTX-
M15+STR+FOX+CTX
103.589 ± 0.6 5197.74 ± 1.3 50.176
CTX-M-
15+CTX+STR+FOX
149.419 ± 0.2 6014.971 ± 0.7 40.255
CTX-M-
15+CTX+FOX+STR
129.165 ± 2.1 6349.142 ± 1.5 49.155
CTX, cefotaxime; STR, streptomycin; FOX, cefoxitin.
Kinetic constants are reported as the average of± standard error from three independent
experiment.
catalytic efficiency (Kcat/Km) of enzyme for all streptomycin
and cephalosporin combinations except for cefotaxime alone.
Calatytic activity (Kcat) of the enzyme with nitrocefin was
found to decrease in all combinations except in presence of
cefotaxime, cefotaxime along with streptomycin and cefoxitinand
streptomycin along with cefoxitin.
DISCUSSION
Fluorescence quenching phenomenon occurs due to various
molecular interactions such as reaction in the excited state when
the electrons in the higher energy level is returned back to lower
energy level, energy transferring, molecular rearrangements
and static and dynamic quenching. It is being carried out
to elucidate the mechanism of interaction of enzyme with
drug molecules (Eftink and Ghiron, 1976; Lakowicz, 1988).
Fluorescence quenching spectra showed the linear dependence
of quenching with different drug combinations which implies
that only one type of quenching mechanism either static or
dynamic dominated in the process (Rehman et al., 2014).
There is significant interaction between CTX-M-15 and drugs
(cefotaxime, cefoxitin, and streptomycin), which was responsible
for the quenching mechanism, inferred by Ksv values (∼ 104
M−1) as shown in Table 1. The kq values in all the cases were of
the order of 1012–1013 M−1s−1 which were found considerably
larger than the maximum dynamic quenching constant ∼
1010 M−1s−1, indicating that the drug-induced quenching of
CTX-M-15 fluorescence was due to complex formation. The
microenvironment around the binding site is becoming less
hydrophobic upon binding of drug by exposing more residues
for interaction as seen by increased values of binding sites.
Greater interaction of CTX-M-15 with cefotaxime than
streptomycin was observed with higher KSV (stern volmer
constant), kq (binding constant) and Ka (association constant).
Decrease in KSV and kq was observed in all the combinations
of drug binding with respect to cefotaxime, suggesting that the
quenching of CTX-M-15 fluorescence was initiated by complex
formation in the ground state rather than by dynamic quenching.
However, increase in the value (n) in all the cases except when
CTX-M-15 interacted with cephalosporins or aminoglycoside,
shows that the microenvironment around the binding site is
becoming less hydrophobic upon binding of drug. It is probably
due to exposure of more binding site residues for interaction.
Maximum drug interaction was observed in all the three triple
combinations of drug and combination of streptomycin and
cefotaxime with CTX-M-15 with the increase in the values
of binding constant comparing to CTX-M-15 with cefotaxime
alone. It indicates that streptomycin induces structural changes
in CTX-M-15 thereby making conditions unfavorable for proper
binding of cefotaxime on its active site for hydrolysis. Hence
decrease in stern volmer and quenching constant was observed.
Far-UV CD spectra showed remarkable change in secondary
structure of CTX-M-15 enzyme at 208 and 222 nm with respect
to native enzyme in all the drug treated combinations. At 208
nm all the combinations showed at least 3.7% decrease in
alpha helix peak. Whereas, on combination with cefotaxime and
streptomycin, 22.2% increase in the peak was observed. At 222
nm all the combinations showed 24.11% increase in the peak.
While, cefotaxime and streptomycin in combination showed
maximum rise in the peak (47.48%) as shown in Figures 3, 4.
Hence the CD-spectral analysis showed disruption in the
overall conformation of CTX-M-15 enzyme upon both single
and combined binding of cephalosporin and aminoglycoside.
Moreover, conformational changes upon binding of cefotaxime
favors hydrolysis, whereas structural changes occurred due
to binding in combination, leading to reduced hydrolysis of
cefotaxime.
Steady-state kinetics data showed the decrease in the affinity
of the CTX-M-15 enzyme toward nitrocefin in the presence
of streptomycin alone and with all other synergistic drug
combinations. Also synergistic drug treatment (in 1:10, 1:10:10,
1:10:10:10 molar ratio of CTXM-15 and drug) decreased the
catalytic efficiency of enzyme to about 27% in all the cases
except in the presence of cefotaxime alone. Enzyme treated with
cefotaxime alone was found 33% more efficient, when combined
along with streptomycin and cefoxitin, the efficiency was reduced
to about 53.4%. Whereas, enzyme treated with streptomycin
alone caused to reduce its efficiency by 25.8%, however when
combined with cefotaxime, its efficiency was decreased by
27.2% with cooperative sigmoidal binding curve (allosteric
behavior). If enzyme combined with cefoxitin, its efficiency was
decreased to about 49.5% while in combination of cefoxitin and
cefotaxime, it was reduced by 41.9%. Hence, the study shows
that the enzyme incubated first with streptomycin then with
cefotaxime in 1:10:10 molar ratio, shows allosteric behavior.
It indicates that streptomycin binding on enzyme promotes
cooperative binding of cefotaxime. Moreover, upon streptomycin
incubation as single and in cefotaxime/cefoxitin/streptomycin
combinations, catalytic efficiency of enzyme was decreased
significantly which supports synergistic effect of two drugs.While
single drug was not effective against multidrug resistant strain
carrying CTX-M-15 enzyme. This can be explained as binding
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FIGURE 6 | Lineweaver-Burk plot. Steady-state kinetics of Nitrocefin hydrolysis by CTX-M-15 in the absence and presence of different combinations of (A)
Cefotaxime/Streptomycin/Cefoxitin and (B) Streptomycin/ Cefotaxime/Cefoxitin at 298K was carried out. The concentration of CTX-M-15 was 8.75 nM while the
concentration of drugs were 87.5 nM in 50mM sodium phosphate buffer, pH 7.4.
of streptomycin may induce structural changes in CTX-M-15,
hence cefotaxime was not hydrolyzed and available to act on
its target in bacterial cells to kill. This is the first time we
have demonstrated a possible mechanism of synergistic effect
of cefoxitin, streptomycin and cefotaxime against multi-drug
resistant strains. In this mechanism based study, streptomycin
induced conformational changes in CTX-M-15 leading to
reduced binding of cefotaxime on its active site of hydrolysis
which in turn decreases its hydrolysis. Consequently, cefotaxime
is available for target site inhibition in bacterial cells (Figure 7).
CONCLUSION
Our study demonstrated first time a possible molecular
mechanism of synergistic effect of combination therapy of
streptomycin and cefotaxime against CTX-M-15 producing
multi-drug resistant strain. The study revealed that binding
of streptomycin induces conformational changes in CTX-M-15
leading to reduced binding of cefotaxime which in turn reduces
its hydrolysis. Consequently, cefotaxime is available for target site
inhibition in bacterial cells.
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FIGURE 7 | Synergistic effect of streptomycin and cefotaxime on CTX-M-15. (A) shows inability of cell killing by cefotaxime due to its hydrolysis by CTX-M-15
enzyme. (B) shows cellular lyses by available un-hydrolyzed cefotaxime due to streptomycin which leads to reduced binding of cefotaxime on its active site of
hydrolysis.
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